Treatment comparison of budesonideformoterol with salmeterolfluticasone propionate in adults aged ≥16 years with asthma: Post hoc analysis of a randomized, double-blind study

Clinical Drug Investigation

Volumn 30, Issue 9, 2010, Pages 565-579

  Kuna, Piotr ^a  

^a Medical University of Lodz ^*  (Poland)

Author keywords

Antiasthmatics; Asthma; Beta 2 adrenergic receptor agonists; Bronchodilators; Budesonide; Budesonideformoterol; Corticosteroids; Fluticasone propionate; Formoterol; Salmeterol; Salmeterolfluticasone propionate; therapeutic use; treatment

Indexed keywords

ADOAIR; BECLOMETASONE PLUS FORMOTEROL; BUDESONIDE PLUS FORMOTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; FOSTER; UNCLASSIFIED DRUG; ANDROSTANE DERIVATIVE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; DRUG DERIVATIVE; ETHANOLAMINE DERIVATIVE; FLUTICASONE, SALMETEROL DRUG COMBINATION; FORMOTEROL; GLUCOCORTICOID; SALBUTAMOL;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMERGENCY WARD; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMAN; INCIDENCE; LUNG FUNCTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PHARYNGITIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; RHINOPHARYNGITIS; RISK REDUCTION; SYMPTOM; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; EMERGENCY HEALTH SERVICE; INHALATIONAL DRUG ADMINISTRATION; KAPLAN MEIER METHOD; LUNG; MIDDLE AGED; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; TIME;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; AGED; AGED, 80 AND OVER; ALBUTEROL; ANDROSTADIENES; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; EMERGENCY SERVICE, HOSPITAL; ETHANOLAMINES; FEMALE; GLUCOCORTICOIDS; HOSPITALIZATION; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; QUALITY OF LIFE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77954628256     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11533450-000000000-00000     Document Type: Article

References (38)

1. National Heart Lung and Blood Institute. Expert panel report 3: guidelines for the diagnosis and management of asthma. 2007 [online].Available fromURL: http://www.nhlbi.nih.gov/ guidelines/asthma/asthsumm.pdf [Accessed 2010 Jan]
2. Global Initiative for Asthma. Global strategy for asthma management and prevention: updated 2009 [online]. Available from URL: www.ginasthma.com [Accessed 2010 Jan]
3. Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement. Asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009; 180 (1): 59-99
4. British Thoracic Society and Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma: a national clinical guideline. 2008 [online]. Available from URL: http://www.brit-thoracic.org.uk [Accessed 2010 Jan]
5. Bateman ED, Boushey HA, Bousquet J, et al. Can guidelinedefined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170 (8): 836-844
6. Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid.Allen& Hanburys Limited UK Study Group. Lancet 1994; 344 (8917): 219-224
7. Ind PW, Dal Negro R, Colman NC, et al. Addition of salmeterol to fluticasone propionate treatment in moderateto-severe asthma. Respir Med 2003; 97 (5): 555-562
8. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164 (8 Pt 1): 1392-1397
9. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337 (20): 1405-1411
10. Shepherd J, Rogers G, Anderson R, et al. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with longacting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over. Health Technol Assess 2008; 12 (19): iii-iv, 1-360
11. van Noord JA, Schreurs AJ, Mol SJ, et al. Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. Thorax 1999; 54 (3): 207-212
12. Nathan RA, Rooklin A, Schoaf L, et al. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study. Clin Ther 2006; 28 (1): 73-85
13. Bateman ED, Britton M, Carrillo J, et al. Salmeterol/ fluticasone combination inhaler: a new, effective and well tolerated treatment for asthma. Clin Drug Investig 1998; 16 (3): 193-201
14. Aubier M, Pieters WR, Schlosser NJ, et al. Salmeterol/ fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respir Med 1999; 93 (12): 876-884
15. Lalloo UG, Malolepszy J, Kozma D, et al. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. Chest 2003; 123 (5): 1480-1487
16. Scicchitano R, Aalbers R, Ukena D, et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 2004; 20 (9): 1403-1418
17. Zetterstrom O, Buhl R, Mellem H, et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J 2001; 18 (2): 262-268
18. Huchon G, Magnussen H, Chuchalin A, et al. Lung function and asthma control with beclomethasone and formoterol in a single inhaler. Respir Med 2009; 103 (1): 41-49
19. Papi A, Paggiaro P, Nicolini G, et al. Beclomethasone/ formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy 2007; 62 (10): 1182-1188
20. Papi A, Paggiaro PL, Nicolini G, et al. Beclomethasone/ formoterol versus budesonide/formoterol combination therapy in asthma. Eur Respir J 2007; 29 (4): 682-689
21. Bousquet J, Boulet LP, Peters MJ, et al. Budesonide/ formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/ fluticasone. Respir Med 2007; 101 (12): 2437-2446
22. Kuna P, Peters MJ, Manjra AI, et al. Effect of budesonide/ formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007; 61 (5): 725-736 (Pubitemid 46587876)
23. O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/ formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171 (2): 129-136
24. Rabe KF, Pizzichini E, Stallberg B, et al. Budesonide/ formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest 2006; 129 (2): 246-256
25. Rabe KF, Atienza T, Magyar P, et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, doubleblind study. Lancet 2006; 368 (9537): 744-753
26. Vogelmeier C, D'Urzo A, Pauwels R, et al. Budesonide/ formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J 2005; 26 (5): 819-828
27. Bateman ED, Silins V, Bogolubov M. Clinical equivalence of salmeterol/fluticasone propionate in combination (50/ 100 microg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma. Respir Med 2001; 95 (2): 136-146
28. van Noord JA, Lill H, Diaz TC, et al. Clinical equivalence of a salmeterol/fluticasone propionate combination product (50/500 mcg) delivered via a chlorofluorocarbon-free metereddose inhaler with the Diskus(TM) in patients with moderate to severe asthma. Clin Drug Investig 2001; 21: 243-255
29. Juniper EF, O'Byrne PM, Guyatt GH, et al. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999; 14 (4): 902-907
30. Juniper EF, Svensson K, Mörk AC, et al. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 2005; 99 (5): 553-558
31. Juniper EF, Buist AS, Cox FM, et al. Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest 1999; 115 (5): 1265-1270
32. Juniper EF, Guyatt GH, Willan A, et al. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994; 47 (1): 81-87
33. Barnes PJ. Scientific rationale for using a single inhaler for asthma control. Eur Respir J 2007; 29 (3): 587-595
34. Palmqvist M, Ibsen T, Mellen A, et al. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 1999; 160 (1): 244-249
35. Palmqvist M, Arvidsson P, Beckman O, et al. Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers. Pulm Pharmacol Ther 2001; 14: 29-34
36. Borgstrom L, Asking L, Thorsson L. Idealhalers or realhalers? A comparison of Diskus and Turbuhaler. Int J Clin Pract 2005; 59 (12): 1488-1495
37. Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180 (8): 741-750
38. Sears MR, Radner F. Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials. Respir Med 2009; 103 (12): 1960-1968